Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ka‐Liong Tan
Observed names:
K. L. TAN,
K.-L. Tan,
K.L. Tan,
Ka Liong Tan,
Ka-Liong Tan,
Tan Ka Liong,
Tan, Ka-Liong
show all 7
Institution:
Universiti Sains Islam Malaysia
Observed institutions:
Universiti Sains Islam Malaysia,
Universiti Sains Malaysia,
National University of Singapore,
John Radcliffe Hospital,
University of Oxford
ORCID:
0000-0001-5811-8018
Observed ORCID:
0000-0001-5811-8018
OpenAlex ID:
A5047362173
Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection
2011
·
Ka Liong Tan
, Ravindran Ankathil
, et al.
·
Journal of Chromatography B
·
27
The Mortality of Exchange Transfusions
1962
·
K. L. TAN
, K. B. PHUA
, et al.
·
The Medical Journal of Australia
·
23
Molecular epidemiology of respiratory viruses among Malaysian Young children with a confirmed respiratory infection during 2014–2015
2019
·
Su Mei Yew
, Ka-Liong Tan
, et al.
·
Journal of Thoracic Disease
·
18
PDF
NUB1 and FAT10 Proteins as Potential Novel Biomarkers in Cancer: A Translational Perspective
2021
·
Maria Arshad
, Nazefah Abdul Hamid
, et al.
·
Cells
·
15
PDF
Zingiber Zerumbet: Pharmacological Values of Zerumbone and the Extraction Technology Evolution
2023
·
Nurul 'Uyun Ahmad
, Mariam Firdhaus Mad Nordin
, et al.
·
Jurnal Teknologi
·
9
PDF
Pharmacokinetics and Bioequivalence Study of a New Branded Generic Moxifloxacin Tablet Among Healthy Volunteers
2021
·
Atiqah Amran
, Ching Yee Tan
, et al.
·
Clinical Pharmacology in Drug Development
·
8
Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach
2016
·
Ka-Liong Tan
, Francesco Pezzella
·
Oncology Letters
·
6
PDF
Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers
2021
·
Nishalini Harikrishnan
, Ka-Liong Tan
, et al.
·
Generics and Biosimilars Initiative Journal
·
5
Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients
2024
·
Ka-Liong Tan
, Syed Haider
, et al.
·
Translational Oncology
·
4
PO-479 NUB1 as a prognostic marker in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
2018
·
K.L. Tan
, F. Pezzella
, et al.
·
ESMO Open
·
4
Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients
2025
·
Maria Arshad
, Amira Raudhah Abdullah
, et al.
·
Biomedicines
·
3
PDF
Antibacterial Potential and Phytochemical Composition in Subcritical Water Extraction of Lempoyang (Zingiber zerumbet)
2025
·
Nurul ‘Uyun Ahmad
, Mariam Firdhaus Mad Nordin
, et al.
·
Tropical Life Sciences Research
·
2
Enhanced Osteoinductive Bone Repair Using Dual Growth Factors (VEGF and BMP-2) with Alendronate in Engineered Hydroxyapatite Scaffold
2025
·
Intan Maslina Musa
, Mohd Riduan Mohamad
, et al.
·
Current Drug Therapy
·
1
Assessment of leaching properties of solid residue from subcritical water extraction of Zingiber zerumbet rhizome
2024
·
N.U. Ahmad
, M.F. Mad Nordin
, et al.
·
BIO Web of Conferences
·
1
PDF
NUB1 protein localization as a prognostic modifier in ER-negative breast cancer
2026
·
Ka-Liong Tan
, Francesco Pezzella
·
Cell Signaling
PDF
Corrigendum to “Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients” [Translational Oncology, volume 49 (2024), 102106]
2025
·
Ka-Liong Tan
, Syed Haider
, et al.
·
Translational Oncology
Translational relevance of AIPL1 and NUB1 in cancer
2017
·
Tan, Ka-Liong
·
Oxford University Research Archive (ORA) (University of Oxford)
NUB1 protein regulates cullins and E3 ligases in estrogen receptor negative breast cancers
2016
·
K.L. Tan
, S. Haider
, et al.
·
European Journal of Cancer
Molecular cochaperone & its deregulation in breast cancer
2015
·
K.-L. Tan
, F. Pezzella
·
Annals of Oncology
PDF
Influence of CYP1A2, CYP3A5 and CYP2C19 Polymorphisms on Imatinib Mesylate Drug Responses in Three Major Asian Ethnic Groups and Variation of IM and Active Metabolite (M1) Trough Level Among Chronic Myeloid Leukemia Patients
2012
·
K.-L. Tan
, S.-H. Gan
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
21
Citation count:
134
H-index:
6
I10-index:
5
Year
Topic
Type